Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1Phase 1 1

Status

Recruiting 4Terminated 1

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5Thoracic 1Head & Neck 1Gynecologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Colorectal Neoplasms 5Squamous Cell Carcinoma of Head and Neck 2Stomach Neoplasms 1Solid Tumors 1Solid Tumor, Adult 1Salivary Gland Neoplasms 1RAS/BRAF Wild-type Advanced Colorectal Cancer Patients 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Metastatic Non-small Cell Lung Cancers 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Adenoid Cystic 1Breast Neoplasms 1

Interventions

Fluorouracil 498Bevacizumab 476Oxaliplatin 450Leucovorin 442Irinotecan 408Cetuximab 318Capecitabine 317pembrolizumab 142Folfox protocol 128Panitumumab 117regorafenib 105Colonoscopy 88Nivolumab 82IFL protocol 81Drug Therapy 77trifluridine tipiracil drug combination 73Radiotherapy 66HMPL-013 65Blood Specimen Collection 52Gemcitabine 49Specimen Handling 47Standard of Care 45Neoadjuvant Therapy 45Magnetic Resonance Spectroscopy 44Biopsy 44Chemotherapy, Adjuvant 41Trifluridine 40atezolizumab 39Cyclophosphamide 39Surveys and Questionnaires 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Colorectal Neoplasms × amivantamab × Clear all
NCT05379595 2026-06-05

OrigAMI-1

Janssen Research & Development, LLC

Phase 1/2 Recruiting
225 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06662786 2026-06-05

OrigAMI-2

Janssen Research & Development, LLC

Phase 3 Recruiting
1,000 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06750094 2026-06-05

OrigAMI-3

Janssen Research & Development, LLC

Phase 3 Recruiting
700 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05845450 2026-03-12

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

Gruppo Oncologico del Nord-Ovest

Phase 2 Recruiting
197 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT05395052 2023-09-21

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
5 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡